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ABSTRACT
Inherited DNA mismatch repair (MMR) defects cause predisposition to colorectal, 
endometrial, ovarian, and other cancers occurring in Lynch syndrome (LS). It is unsettled 
whether breast carcinoma belongs to the LS tumor spectrum. We approached this 
question through somatic mutational analysis of breast carcinomas from LS families, 
using established LS-spectrum tumors for comparison. Somatic mutational profiles of 578 
cancer-relevant genes were determined for LS-breast cancer (LS-BC, n = 20), non-carrier 
breast cancer (NC-BC, n = 10), LS-ovarian cancer (LS-OC, n = 16), and LS-colorectal cancer 
(LS-CRC, n = 18) from the National LS Registry of Finland. Microsatellite and MMR protein 
analysis stratified LS-BCs into MMR-deficient (dMMR, n = 11) and MMR-proficient (pMMR, 
n = 9) subgroups. All NC-BCs were pMMR and all LS-OCs and LS-CRCs dMMR. All but one 
dMMR LS-BCs were hypermutated (> 10 non-synonymous mutations/Mb; average 174/
Mb per tumor) and the frequency of MMR-deficiency-associated signatures 6, 20, and 26 
was comparable to that in LS-OC and LS-CRC. LS-BCs that were pMMR resembled NC-BCs 
with respect to somatic mutational loads (4/9, 44%, hypermutated with average mutation 
count 33/Mb vs. 3/10, 30%, hypermutated with average 88 mutations/Mb), whereas 
mutational signatures shared features of dMMR LS-BC, LS-OC, and LS-CRC. Epigenetic 
regulatory genes were significantly enriched as mutational targets in LS-BC, LS-OC, and 
LS-CRC. Many top mutant genes of our LS-BCs have previously been identified as drivers 
of unselected breast carcinomas. In conclusion, somatic mutational signatures suggest 
that conventional MMR status of tumor tissues is likely to underestimate the significance 
of the predisposing MMR defects as contributors to breast tumorigenesis in LS.
INTRODUCTION
Lynch syndrome (LS) is a prevalent cancer 
predisposition syndrome, originally defined by the 
Amsterdam criteria [1, 2] and later by pathogenic or 
likely pathogenic germline variants of the DNA mismatch 
repair (MMR) genes MLH1, MSH2, MSH6, or PMS2 [3]. 
Compared to the general population, carriers of such variants 
have significantly increased risks of cancers of the colon 
and rectum, endometrium, ovary, kidney and urinary tract, 
upper gastrointestinal tract, and certain other organs [4]. 
In comparison with earlier retrospective and family-based 
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studies, recent prospective studies have arrived at somewhat 
lower age-specific risk estimates for cancers occurring in 
MMR variant carriers; moreover, penetrance and expression 
patterns greatly depend on the MMR gene involved [5]. 
Among individual MMR genes, pathogenic variants in 
MLH1 and MSH2 have the highest and PMS2 the lowest 
penetrance, and MSH6 variants underlie a sex-limited trait 
with a high risk of gynecological cancers in females [5].
Evaluations of breast cancer risk in LS have arrived 
at conflicting findings. Win et al. [6] conducted a systematic 
review on breast cancer in LS and identified 8 studies 
reporting an elevated (2–18-fold) risk, whereas the remaining 
13 studies found no significantly increased risk. Moreover, 
breast cancer risk has been reported to be specifically 
associated with certain MMR genes, including MLH1 (vs. 
MSH2 [7, 8]), MSH2 [9], and MSH6 and PMS2 (vs. MLH1 
and MSH2 [10, 11]. Variability in results may reflect different 
methods of ascertainment, cohort sizes, ethnicity, or other 
factors. In the large multicenter prospective investigation by 
Dominguez-Valentin et al. [5], the cumulative risk of breast 
cancer to 75 years of age was 12–15%, similar across all four 
MMR genes and representing only a marginal increase vs. 
average population.
Instability at microsatellite sequences (MSI) and absent 
MMR protein expression by immunohistochemical analysis 
of tumor tissues are common pre-screening methods for LS. 
Such methods classified 51% (62/122) of breast carcinomas 
from predisposing MMR gene variant carriers as MMR-
deficient (dMMR) in studies reviewed by Win et al. [6]. Since 
deficient MMR is rare (< 2%) in breast carcinomas from the 
average population [12], the result implied a role for MMR 
deficiency in LS-associated breast cancer. Furthermore, 
abnormal immunohistochemistry and hypermutated tumor 
phenotype, combined with early onset of the disease (29 
years), recently led to the suggestion that breast cancer is 
part of the tumor spectrum of the constitutional mismatch 
repair deficiency (CMMRD) syndrome caused by biallelic 
pathogenic germline variants of MMR genes [13].
We previously showed that breast carcinoma from 
carriers of inherited MMR defects resembles common 
breast carcinoma with respect to many clinicopathological 
features, such as mean age at onset over 50 years; 
however, the fact that over half of the tumors were dMMR 
suggested etiologic association to LS [14]. In the present 
investigation, we use somatic mutation profiling of breast 
cancers vs. established LS-spectrum tumors as a tool to 
address the relationship between breast cancer and LS.
RESULTS
Clinicopathological characteristics of patients 
and tumors
This study was designed to investigate if breast 
carcinoma, the most common form of cancer in the general 
female population, is in LS individuals molecularly 
associated with their inherited MMR defects. To this end, 
carcinomas of the breast (BC), ovary (OC), and colon and 
rectum (CRC) were ascertained through the National LS 
Registry of Finland. Breast carcinomas from carriers of 
pathogenic or likely pathogenic germline MMR variants 
(LS-BC, n = 20) were compared to breast carcinomas 
from patients shown not to carry the predisposing MMR 
gene variant of their families (NC-BC, n = 10) and to 
established LS-spectrum tumors from pathogenic MMR 
gene variant carriers (LS-OC, n = 16, and LS-CRC, n = 18) 
(Tables 1 and 2). The different predisposing MMR genes 
were roughly similarly distributed across all LS groups, 
with MLH1 associated with 67%, MSH2 with 17%, and 
MSH6 with 17% of the total 54 tumors (Table 2).
Baseline characterization included MMR status 
of the tumors, where the absence of MMR protein by 
IHC, presence of MSI, or both were required for MMR-
deficiency (see Materials and Methods). While all LS-OCs 
and LS-CRCs were MMR-deficient (dMMR) and all NC-
BCs MMR-proficient (pMMR), LS-BCs broke down into 
dMMR (n = 11) and pMMR (n = 9) subgroups (Table 1). 
LS-BCs that were dMMR were diagnosed at the mean age 
of 53 years vs. 63 years for pMMR LS-BCs (p = 0.036). 
NC-BCs were diagnosed at 59 years on the average (non-
significant difference relative to dMMR LS-BC).
Mechanisms of second allele inactivation of 
MMR genes in LS-BCs
LOH, somatic mutation, and promoter methylation 
were considered as possible second hits (Tables 1 
and 2, Supplementary Table 1). In dMMR LS-BC, the 
primary mechanism of the second hit was LOH (6/11, 
55%) whereas only 2/9 (22%) pMMR LS-BCs showed 
LOH. In pMMR LS-BC, somatic point mutation (s) 
of the predisposing MMR genes was the predominant 
mechanism (3/9, 33% vs. 4/11, 36% in dMMR LS-BC). 
Promoter methylation analysis by MS-MLPA indicated 
that none of the MLH1-deficient samples exhibited 
promoter methylation of MLH1 as a second hit. In 
summary, all but one dMMR LS-BCs (10/11, 91%) had a 
detectable second hit, compared to 5/9 (56%) of pMMR 
LS-BCs (statistically non-significant). The patterns of two-
hit inactivation of the predisposing MMR genes in LS-BC 
closely resembled those previously observed for LS-OC 
and LS-CRC, where a detectable second hit, mostly LOH, 
was present in 10/16 (63%) of LS-OCs and 15/18 (83%) 
of LS-CRCs (Table 2 and ref [15]).
Mutation profiles of 578 cancer-relevant genes
Numbers of mutations
Somatic mutational analysis identified an average of 
174 non-synonymous somatic mutations per Mb in dMMR 
LS-BCs, compared with 33/Mb in pMMR LS-BCs (non-
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significant difference) and 88/Mb in NC-BCs (borderline 
significant relative to dMMR LS-BC, p = 0.053) (Table 2). 
The corresponding mutation counts in LS-OCs and LS-
CRCs were 184/Mb and 172/Mb, respectively.
All but one dMMR LS-BCs (10/11, 91%) were 
hypermutated (> 10 non-synonymous mutations per Mb). The 
single non-hypermutated tumor (BC11_31533T) was from a 
carrier of the most prevalent Finnish founder variant in MLH1 
and showed LOH at MLH1 and absent MLH1 protein, but 
stable microsatellites (Table 1). The fraction of hypermutated 
dMMR LS-BC tumors was comparable to that of dMMR LS 
tumors of other organs (13/16, 81% for LS-OC and 18/18, 
100% for LS-CRC) (Table 2). Among pMMR LS-BCs, 4/9 
(44%) were hypermutated; of these, an inactivating somatic 
“hit” to the predisposing MMR gene was detectable in three 
and consisted of somatic mutation in all cases (Table 1).
Interestingly, the NC-BC group, too, revealed 
a hypermutated subset (3/10, 30%) (Tables 1 and 2). 
Double somatic non-synonymous point mutations in 
MMR genes were identified in all three hypermutated 
NC-BCs, affecting MLH1 in two tumors (BC15_31696T 
and BC20_33207T), and MSH2 and MSH6 in one tumor 
(BC16_33205T) (Supplementary Table 2). All MMR 
gene mutations occurred with allele frequencies below 
25% and no MSI-high or IHC abnormality was present in 
the tumors. It is possible that the results reflected clonal 
heterogeneity without actual two-allele inactivation in 
any subclone. To search for alternative explanations for 
the high mutational loads, the hypermutated pMMR breast 
carcinomas (LS and NC cases) were Sanger-sequenced for 
POLE exon 9 and 13 and POLD1 exon 11; no mutations 
were identified in any cases successful in analyses.
Table 1: Molecular characteristics of breast carcinomas case by case














C BC5_31814T MLH1 ex 16, 3.5 kb genomic deletion (Mut I) negat MSS L 141
BC6_31489T MLH1 ex 16, 3.5 kb genomic deletion (Mut I) negat MSI L, s 725
BC11_31501T MLH1 ex 16, 3.5 KB genomic deletion (Mut I) negat MSI L 24
BC11_31533T MLH1 ex 16, 3.5 Kb genomic deletion (Mut I) negat MSS L 5
BC12_31491T MLH1 ex 16, 3,5 kb genomic deletion (Mut I) negat MSI None 22
BC14_33229T MLH1 ex 16, 3.5 kb genomic deletion (Mut I) negat MSS s 662
BC9_33225T MLH1 c.454-1G>A (mutation II) negat MSI L 29
BC7_33223T MSH2 c.187delG negat MSI L 15
BC37_33228T MSH2 ex 1-7 genomic deletion/MLPA negat MSI s 12
BC1_33203T MSH6 ex 1-2 genomic deletion/MLPA negat MSS s 35







C BC5_31495T MLH1 ex 16, 3.5 kb genomic deletion (Mut I) posit MSS None 31
BC13_31486T MLH1 ex 16, 3.5 kb genomic deletion (Mut I) posit MSS s 85
BC4_31514T MLH1 ex 16, 3.5 kb genomic deletion (Mut I) posit MSS L 4
BC38_31510T MLH1 c.454-1G>A (mutation II) posit MSS s 53
BC8_33226T MSH2 ex 1-16 genomic deletion/MLPA posit MSS None 8
BC10_33221T MSH2 c.1738insA posit MSS L 2
BC2_31518T MSH6 ex 1-2 genomic deletion/MLPA posit MSS s 108
BC39_33217T MSH6 ex 1-2 genomic deletion/MLPA posit MSS ND 2




C BC24_31711T Non-carrier posit MSS N/A 1
BC23_33198T Non-carrier posit MSS N/A 1
BC21_31702T Non-carrier posit MSS N/A 5
BC20_33207T Non-carrier posit MSS N/A (ds) 306
BC19_31706T Non-carrier posit MSS N/A 2
BC18_33215T Non-carrier posit MSS N/A 3
BC16_33205T Non-carrier posit MSS N/A (ds) 393
BC43_33196T Non-carrier posit MSS N/A 5
BC15_31696T Non-carrier posit MSS N/A (ds) 161
BC17_31692T Non-carrier posit MSS N/A 2
*L, LOH; s, somatic mutation; ds, double somatic mutation.
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Top mutant genes
Mutant allele frequencies of at least 25% and 
involvement in approximately one-third or a higher 
proportion of the tumors were considered as indicators 
of possible cancer driver nature, as outlined in our 
previous study [15]. In dMMR LS-BC, 18 genes 
fulfilled these requirements (were affected with high-
frequency mutations in a minimum of 27% of the tumors; 
Supplementary Table 3). The 18 “top mutant” genes 
included 5 known to participate in epigenetic regulation 
and 4 involved in DNA repair, which suggested significant 
enrichment when compared to the shares of epigenetic 
regulatory genes and DNA repair genes in the entire 
panel of 578 genes (5/18 vs. 47/578, p = 0.010, and 
4/18 vs. 45/578, p = 0.043, respectively). Details of all 
mutations affecting the 18 top mutant genes are described 
in Supplementary Table 4. Fewer top mutant genes were 
identified for pMMR LS-BC and NC-BC by an analogous 
selection procedure (Supplementary Table 3).
Figure 1 shows the involvement of the 18 dMMR 
LS-BC-associated genes in the remaining carcinoma 
groups, with each group compared against dMMR LS-BC. 
Due to the modest sample sizes, no high-level significant 
differences were observed; however, some observations 
can be made. MMR-proficient breast carcinoma groups 
(pMMR LS-BC and NC-BC) revealed comparable 
patterns, which often deviated from the dMMR LS-
BC mutational pattern, implying the effect of MMR 
proficiency/deficiency (Figure 1A and 1B). The three 
MMR-deficient carcinoma groups (dMMR LS-BC, LS-
OC, and LS-CRC) showed similarities and differences 
likely to at least in part reflect the tissues of origin (Figure 
1C and 1D).
According to the predicted consequences, non-
synonymous somatic mutations were classified into non-
truncating (missense or in frame insertion/deletion) and 
truncating (frameshift or nonsense). As expected, the 
relative proportion of truncating mutations affecting our 
top mutant genes was higher in dMMR LS-BC compared 
to pMMR LS-BC (Supplementary Figure 1).
Mutational signature analysis
Somatic non-synonymous (high- and low-
frequency) mutations detected in the panel of 578 
genes were used to determine mutational signatures for 
each group of tumors (Figure 2) As the total number of 
mutations was low in a proportion of tumors, we preferred 
not to compare individual tumors, but instead determined 
group-specific averages for mutational signatures and 














(n = 18) 
Average age of onset 53 63 59 46 44
Mean no. of non-synonymous 
somatic mutations 696 (174/Mb) 131 (33/Mb) 352 (88/Mb) 735 (184/Mb) 689 (172/Mb)
Proportion hypermutated [> 10 
(ns) mutations per Mb] 10/11 (91%) 4/9 (44%) 3/10 (30%) 13/16 (81%) 18/18 (100%)
Predisposing gene
MLH1 7/11 (64%) 4/9 (44%)
N/A
13/16 (81%) 12/18 (67%)
MSH2 2/11 (18%) 2/9 (22%) 3/16 (19%) 2/18 (11%)
MSH6 2/11 (22%) 3/9 (33%) 0 4/18 (22%)
Two-hit inactivation
Germline mutation + LOH 6/11 (55%) 2/9 (22%)
N/A
7/16 (44%)XXX 9/18 (50%)XXX
Germline mutation + somatic 
point mutation (s) 4/11 (36%) 3/9 (33%) 3/16 (19%)XXX 6/18 (33%)XXX
No obvious second hit 1/11 (9%) 3/9 (33%) 1/16 (6%)XXX 2/18 (11%)XXX
ND 0 1/9 (11%)* 5/16 (31%)XXX 1/18 (6%)XXX
Mutational signatures
Average 6 0,072 0,088 0,017 0,124 0,115
Average 20 0,007 0,138 0,030 0,027 0
Average 26 0,036 0 0 0,006 0,013
Average 6, 20, or 26 0,115 0,226 0,047 0,157 0,128
N/A, Not applicable, *Second hit analysis was inconclusive in one tumor because LOH analysis failed, XXX Based on data in Porkka et al. 2017.
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used these for group-wise comparisons. Figure 2A shows 
the distribution of the 96 possible trinucleotide mutations 
[16] in breast carcinomas. Previous studies have linked 
C > T transitions at NpCpG sites to MMR deficiency 
[16]. Such mutations represented the most frequent type 
of substitutions in both the dMMR and pMMR subsets of 
LS-BC and were less common in NC-BC. Thirty reference 
mutational signatures are indexed in COSMIC, and Figure 
2B shows the relative percentages of these signatures in 
BC, OC, and CRC. Among the main MMR-deficiency 
associated signatures 6, 20, and 26 [16], signature 6 was 
well represented in all tumor groups from originating 
from carriers of inherited MMR gene defects, including 
LS-BC (both dMMR and pMMR), LS-OC, and LS-
CRC. Signature 20 was prominent in pMMR LS-BC. 
When the average frequencies of signatures 6, 20, and 
26 were combined, dMMR LS-BC (0.115) and pMMR 
LS-BC (0.226) resembled LS-OC (0.157) and LS-CRC 
(0.128), whereas the share of MMR-deficiency associated 
signatures in NC-BC was clearly lower (0.047) (Table 2). 
The POLE-associated signature 10 [16] was absent in 
our entire breast cancer series. Of curiosity, all breast 
carcinoma subgroups (LS and NC) shared a notable 
signature 30 (Figure 2B), recently linked to defective 
base excision repair characteristic of breast and other 
carcinomas from biallelic NTHL1-mutation carriers [17]. 
NTHL1 was not included in our CCP panel, and the origin 
of signature 30 in our series remains unknown.
DISCUSSION
The standardized incidence ratio of breast cancer in 
the Finnish LS families is not elevated [18]. Moreover, 
breast carcinoma from LS patients is not associated with 
any specific histological phenotype or clinical features that 
would distinguish it from breast carcinomas that occur 
sporadically. LS-associated breast carcinoma is typically 
ductal and diagnosed above 50 years of age on the average 
[19–22]. Hormone receptor status may vary: Walsh et al. 
[22] observed that most dMMR breast carcinomas from 
LS patients were hormone receptor negative compared 
to the pMMR subgroup, whereas the majority of LS 
breast carcinomas from our series were estrogen receptor-
positive (15/18, 83%) and no difference between the 
dMMR and pMMR subgroups was observed. Like the 
series of Walsh et al. [22], our LS breast cancers were 
predominantly HER2-negative (15/18, 83%).
Microsatellite and immunohistochemical analysis 
divided our LS breast carcinomas into dMMR (55%) and 
pMMR (45%) subgroups in agreement with published 
studies (average 51% dMMR [6];). We have previously 
noted that immunohistochemical analysis is more sensitive 
than MSI to detect MMR deficiency in breast and other 
cancers from LS patients [14]. This likely reflects 
clonal heterogeneity characteristic of LS and sporadic 
MMR-deficient tumors [23, 24]. Consequently, all 
(100%) dMMR LS-BCs revealed immunohistochemical 
Figure 1: Top mutant genes across tumor types. Involvement of 18 LS-BC-associated top mutant genes (x-axis) in the dMMR 
subset of LS-BC (dark blue bars in (A–D), compared to the pMMR subset of LS-BC (turquoise bars in A), non-carrier BC (light blue bars 
in B), LS-OC (orange bars in C), and LS-CRC (green bars in D).
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abnormality, but only 6 (55%) showed MSI-high. Neither 
MSI nor immunohistochemical change was present in the 
pMMR subgroup of LS-BCs.
Incorporation of mutational signatures which reflect 
the underlying pathophysiologic processes [16] may 
increase sensitivity even further. By studying large series of 
unselected breast carcinomas by genome-wide sequencing, 
Davies et al. [25] found that mutational signatures 6, 20, 
and 26 recognized MMR deficiency more faithfully than 
sequencing of MMR genes for mutations or analyzing 
exome data for MSI. We used non-synonymous mutations 
of 578 genes as the basis of mutation signature analysis. 
This limitation must be kept in mind when interpreting 
differences in mutation spectra, although targeted capture 
by panel sequencing and/or restriction to non-synonymous 
mutations have turned out informative in previous studies 
[26, 27]. The combined average proportion of MMR-
deficiency-associated signatures, while low in NC-BC, was 
in our dMMR subset of LS-BC comparable to the averages 
observed in the established LS-spectrum tumors LS-OC 
and LS-CRC, and in the pMMR subset of LS-BC even 
higher (Table 2), suggesting that inherited MMR deficiency 
was likely to play an important role in the etiology of LS-
BC irrespective of IHC/MSI status.
The total mutational burden offers another 
opportunity to reveal MMR deficiency. Nowak et al. 
[27] compared panel sequencing results from unselected 
colorectal carcinomas with immunohistochemical and MSI 
Figure 2: Mutational signatures of tumor groups. (A) Distributions of the average fractions of each of the 96 possible trinucleotide 
substitutions across dMMR LS-BCs, pMMR LS-BCs, and NC-BCs. (B) Proportions of COSMIC signatures 1–30 in LS-CRC, LS-OC, 
dMMR LS-BC, pMMR LS-BC, and NC-BC, based on average frequencies across each group. Signatures with average frequencies below 
0.05 are combined into the ‘Other’ group.
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data and found that false negative results relative to MSI 
were attributable to tumor heterogeneity, whereas false 
positive results were explained by POLE mutations. Using 
the commonly accepted threshold of over 10 somatic 
mutations/Mb [28], 100% LS-CRCs and 91% dMMR LS-
BCs were hypermutated, compared to 81% of LS-OCs 
and 44% of pMMR LS-BCs (Table 2). Importantly, the 
NC-BC group also had a notable hypermutated subset 
(3/10, 30%) in the absence of MSI or extinct MMR protein 
expression or evidence of DNA polymerase proofreading 
defects. While somatic low-frequency mutations were 
detected in MMR genes and might play a role, the ultimate 
mechanism of hypermutated phenotype in NC-BC breast 
carcinomas remained unsettled.
Even for such cancers whose risks have consistently 
been shown to be elevated in LS compared to the average 
population, considerable MSS fractions exist. For 
example, brain tumors we previously examined from 
LS patients all lacked MSI-high [29]. Additionally, one-
fourth of colorectal adenomas developing in LS patients 
are pMMR by immunohistochemical and MSI analysis, 
suggesting that MMR deficiency is not a prerequisite for 
tumor formation [30, 31]. In LS, even immunoactivation 
may take place in premalignant lesions that have neither 
dMMR nor elevated somatic mutational loads [32]. 
Significant heterogeneity has been demonstrated on 
genome-wide level: genomic and transcriptomic analyses 
conducted by Binder et al. [33] divided LS-CRCs into two 
subgroups, one with high numbers of somatic mutations 
reminiscent of sporadic MSI CRC and another one with 
lower mutational loads resembling sporadic MSS CRC. 
As for mechanisms that might mediate predisposition to 
pMMR cancers in carriers of inherited MMR defects, 
several possibilities exist. Apart from the repair of 
replication errors, the MMR system has many other anti-
carcinogenic functions, such as cell cycle checkpoint 
control in response to DNA damage [34]. For MLH1, 
the predominant predisposing gene among our LS-BC 
cases, it was demonstrated that even low reductions 
of the protein product can impair cell cycle checkpoint 
activation while the cells remain MMR-proficient [35]. 
Chromosomal segregation represents another function 
sensitive to the dosage of the MLH1 gene product in an 
analogous manner [36]. Finally, MMR proteins participate 
in additional repair mechanisms, whose failure may 
contribute to hypermutability despite MMR proficiency; 
for example, MSH2 is part of BRCA1-associated genome 
surveillance complex that protects against DNA double-
strand breaks [37]. In this context, it is of interest that 
the pMMR subgroup of LS-BC had a notable signature 3 
(Figure 2B) which is known to be associated with defects 
in homologous recombination [16].
A whole-genome investigation of 560 breast 
carcinomas [38] identified TP53, PIK3CA, MYC, CCND1, 
PTEN, ERBB2, FGFR1, GATA3, RB1, and MAP3K1 as the 
most frequently mutant genes. Of these, TP53, PIK3CA, 
PTEN, and ERBB2 were among the top mutated genes 
selected by the criteria we used (at least 27% of tumors 
affected by mutations with allele frequency 25% or 
higher) (Figure 1). While seldom affected in LS-CRC and 
LS-OC, TP53 was mutant in 5/20 (25%) of our LS-BCs. 
Interestingly, somatic TP53 mutations in breast cancer 
were recently associated with immune-rich status [39]. 
In a function-based classification, epigenetic regulatory 
genes and DNA repair genes were significantly enriched 
as mutational targets among our LS-BC-associated genes. 
The histone lysine methyltransferases KMT2C (MLL3) and 
KMT2D (MLL2) (Figure 1) also belong to the driver genes 
detected by Nik-Zainal et al. [38]. Mutations in these genes 
may alter the expression of other genes (e. g., inactivating 
KMT2C mutations were shown to downregulate genes 
involved in homologous recombination-mediated DNA 
repair, making the tumor cells chromosomally unstable 
[40];) or be harmful by other mechanisms (e. g., KMT2D 
mutations were found to increase mutational burden and 
genome instability in cancer through transcription stress 
[41],). Combined with our previous findings [15], frequent 
mutations in epigenetic regulatory genes appear to be a 
common feature of LS tumors, applicable to LS-OC and 
LS-CRC as well.
Mismatch repair deficiency and the associated 
hypermutability may indicate responsiveness to PD-1 
blockade, as recently reported for metastatic dMMR breast 
cancer [42]. Rampias T et al. [40] showed that inactivating 
KMT2C mutations (see above) caused sensitivity to 
PARP1/2 inhibition through synthetic lethality. Several 
other genes involved in LS-associated breast cancer may 
also be clinically actionable [43].
In conclusion, we demonstrate that LS-BCs which 
fell into dMMR and pMMR subsets by conventional 
methods shared MMR-deficiency-associated consensus 
signatures with the established LS spectrum tumors 
LS-OC and LS-CRC. Our results suggest that inherited 
MMR deficiency likely contributed to the development 
of LS-BC through disruption of MMR-related and non-
MMR-related functions, thereby facilitating tumor 
initiation or progression. As this study was based on 
a modest number of cases retrieved from a national LS 
registry and the predisposing genes (MLH1, MSH2, and 
MSH6) were unevenly distributed, our tumors may not be 
considered representative of all tumors of the respective 
organs occurring in LS. Therefore, our results need to be 




All available breast carcinomas (LS-BC) (n = 20) and 
corresponding normal DNA samples from 17 females were 
collected from the National LS registry of Finland (LSRFi) 
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that includes information of approximately 300 LS families 
and over 1600 tested carriers of inherited MMR defects. All 
predisposing variants were pathogenic or likely pathogenic, 
representing pathogenicity classes 5 and 4, respectively. 
MLH1 was affected in 9 patients (with 11 tumors) of 
which 7 patients had the prevalent Finnish founder variant 
(“mutation I”), which is a 3.5-kb genomic deletion of exon 
16 and its flanking introns [44]. Four individuals (with one 
tumor each) had a pathogenic or likely pathogenic germline 
variant in MSH2, and one individual with two tumors 
had a predisposing variant in MSH6 (Table 1). Estrogen 
receptor (ER) status was positive in 15 LS-BC samples, 
3 tested negative and the status could not be determined 
for 2. Human epidermal growth factor receptor 2 (HER2) 
status was positive for 3, negative for 15, and could not be 
determined for 2 LS-BC tumors.
For comparison, 10 breast carcinomas from non-
carrier members of families registered in LSRFi were 
included (the NC-BC group in Table 1). The ER status and 
HER2 status (mainly positive and negative, respectively) 
of NC-BCs matched with those of LS-BCs. The average 
age at breast cancer diagnosis was similar in LS and NC-
BC groups (57 and 59 years, respectively). In addition, we 
analyzed 16 LS ovarian and 18 LS colorectal carcinomas 
(LS-OCs and LS-CRCs, respectively) from the same 
registry [15].
All tumor samples and the majority of normal DNA 
samples (19/27) were formalin-fixed paraffin embedded 
(FFPE) samples. DNA was extracted from selected high tumor 
percentage areas according to the modified protocol described 
by Isola et al. [45]. The remaining eight normal DNA samples 
were extracted from blood according to the non-enzymatic 
protocol described by Lahiri and Nurnberger [46].
This study was approved by the Institutional 
Review Board of the Helsinki University Central Hospital 
(466/E6/01). The National Supervisory Authority for 
Welfare and Health (Dnro 1272/04/044/07 and Dnro 
10741/06.01.03.01/2015) approved the collection of 
archival specimens. Informed consent procedures defined 
by the Ethics approvals were followed in sample collection.
MMR status of breast carcinomas
Results from immunohistochemical (IHC) analyses 
for MMR protein expression and microsatellite instability 
(MSI) analyses were available from our previous 
investigation [14]. Breast carcinomas were considered 
MMR-deficient (dMMR) when MMR protein was absent 
by IHC and/or the tumors showed MSI (at least one of 
the two mononucleotide repeat markers BAT25 and BAT26 
was unstable).
MLH1 promoter methylation analysis
Promoter methylation status of MLH1 in breast 
cancer samples with deficient MLH1 expression was 
determined by methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA) using 
SALSA MS-MLPA probemix ME001-C1 (MRC Holland, 
Amsterdam, Netherlands), as described in Lotsari et al. 
[14]. Of the two MLH1-associated probe pairs, the one 
closest to the transcription start site was considered. 
Methylation dosage ratio of 0.25 or higher (corresponding 
to at least 25% of methylated DNA) provided the best 
discrimination between tumor and paired normal DNA and 
was used as the cut-off for hypermethylation [14].
Comprehensive cancer panel (CCP) sequencing
Tumor and matching normal DNA samples from LS-
BC and NC-BC cases were sequenced in the Institute for 
Molecular Medicine Finland (FIMM) on Illumina HiSeq 
2500 platform (San Diego, CA, USA) using Nimblegen 
Comprehensive cancer panel (Roche Diagnostics). The 
panel is a 4 Mb design covering 578 known cancer-related 
genes and their intronic regions compiled from the Sanger 
Institute Cancer Gene Census database (https://www.ncbi.
nlm.nih.gov/pubmed) and the NCBI Gene tests database 
(https://www.ncbi.nlm.nih.gov/). ThruPLEX® DNA-seq 
Kit was used for library preparation, and exon capture 
was conducted according to the manufacturer’s protocol 
(Rubicon Genomics). The variant calling pipeline is 
described in detail by Sulonen et al. [47]; in the present 
study, we used version 3.6. To enable comparison with 
breast cancer data, LS-OC and LS-CRC data generated 
previously [15] were re-analyzed with the VCP 3.6 pipeline. 
Supplementary Table 5 shows performance characteristics 
of breast carcinomas. The mean target coverage was 160-
fold for dMMR LS-BC, 114-fold for pMMR LS-BC, and 
78-fold for NC-BC. Please see ref [15]. for the performance 
characteristics of LS-OC and LS-CRC.
Somatic mutation analysis of CCP data
Paired tumor and normal sample sequencing data were 
analyzed by the VarScan 2 mutation detection algorithm 
version 2.3.2 [48] to identify non-synonymous (missense, 
nonsense, frameshift, in-frame coding deletion/insertion and 
splice site) changes of somatic origin. Variants with VarScan 
somatic p-value below 0.01 were considered significant 
and are referred to as `somatic mutations` throughout this 
paper. Such variants had the possibility of being pathogenic 
according to traditional pathogenicity classes 3–5 and 
were selected for subsequent analyses. The variants were 
categorized based on variant allele frequency (low frequency 
< 0.25 vs. high frequency ≥ 0.25) and effect (truncating vs. 
non-truncating) as described previously [15, 49].
POLD1 and POLE sequencing
Hypermutated pMMR breast carcinomas were 
screened for proofreading mutations in POLE exons 9 
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and 13 by Sanger sequencing with primers described by 
Church et al. [50]. POLD1 exon 11 was examined by 
Sanger sequencing with primers described in Valle et al. 
2014 [51].
Two-hit inactivation of MMR genes
Somatic point mutations in MMR genes that 
could serve as second hits were identified from the CCP 
sequencing data. Loss of heterozygosity (LOH) was 
also evaluated as a possible second hit and the method 
depended on the type of the predisposing MMR gene 
alteration. When the predisposing MMR gene change 
was a point mutation, VarSeq software (GoldenHelix®) 
with VCP filtered CCP sequencing data (. vcf-files) 
was used to compare sequence data from tumor and 
their corresponding normal samples. The variant allele 
reads (Alt) to reference allele reads (Ref) ratio was 
determined in tumor (T) and normal (N) DNA, and LOH 
ratio (R) calculated as follows: R = (Alt: Ref)T/(Alt: 
Ref)N. The thresholds for “strict” LOH and “putative” 
LOH were as specified by Ollikainen et al. [52]. When 
the predisposing change was a large deletion, MLPA-
based data (SALSA P003-C1 for MLH1 and MSH2 and 
SALSA 072-C1 for MSH6; MRC Holland, Amsterdam, 
The Netherlands) were utilized for LOH analysis and 
the results interpreted according to Zhang et al. [53]. 
“Putative” and “strict” LOH are called LOH throughout 
this paper. In MLH1-associated cases, promoter 
methylation of MLH1 was tested as a second hit by 
MS-MLPA as described above under “MLH1 promoter 
methylation analysis”.
Definition of top-mutated genes
We used a procedure developed in our previous 
study [15]. In brief, for each of the 578 genes of the CCP 
panel, we determined the proportion of tumors having 
that gene in a mutant form. We focused on mutations 
with high (≥ 25%) variant allele frequency to increase 
the likelihood of clonal (driver) as opposed to subclonal 
(passenger) mutations [54]. Based on the distribution of 
the proportions of tumors with individual genes mutant, 
a cut-off of one-third was established to divide the genes 
into top-mutated and less commonly mutated categories. 
Finally, a pathway annotation was performed on each top 
gene according to GeneCards (http://www.genecards.org) 
and relevant publications from PubMed (https://www.ncbi.
nlm.nih.gov/pubmed).
In silico predictions of somatic mutations
We utilized in silico predictions from Varsome-
database [55] to assign a pathogenic significance category 
for somatic variants identified for MMR genes in the 
second hit analysis.
Mutational signature analysis
Mutational signatures by Alexandrov et al. [16] were 
determined by applying the R package deconstructSigs 
[56] to significant (p < 0.01) non-synonymous somatic 
mutations from VarScan2 analysis (see “Somatic mutation 
analysis of CCP data” above) using default parameters 
against signatures recognized by the COSMIC database 
[57]. In the analysis, deconstructSigs determines the 
mutational profile of tumor samples by applying a multiple 
linear regression model to the input data. Mutational 
signatures were called for each sample individually and 
collectively for groups of samples (BC vs. OC vs. CRC; 
dMMR vs. pMMR).
Statistical analyses
Statistical analyses were performed using IBM 
SPSS Statistical software version 25.0 (IBM SPSS 
Inc., Chicago, IL, USA). The applicability of the data 
for parametric vs. non-parametric tests was tested first. 
Statistical significance of distribution of mutated genes 
in independent groups was evaluated using the Mann-
Whitney U test. Pairwise comparisons of frequency data 
were conducted by the Fisher’s exact test. Differences with 
p-value < 0.05 (two-tailed) were considered significant.
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